Table 2.
Summary of response rates before and after propensity score matching.
| Best overall response, n (%) | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| T+S (n = 43) | T+S+ICIs (n = 33) | p value | T+S (n = 29) | T+S+ICIs (n = 29) | p value | |
| Complete response | 0 (0) | 0 (0) | > 0.999 | 0 (0) | 0 (0) | > 0.999 |
| Partial response | 12 (27.9) | 20 (60.6) | 0.004 | 10 (34.5) | 17 (58.6) | 0.065 |
| Stable disease | 12 (27.9) | 8 (24.2) | 0.719 | 7 (24.1) | 7 (24.1) | > 0.999 |
| Progressive disease | 19 (44.2) | 5 (15.2) | 0.007 | 12 (41.4) | 5 (17.2) | 0.043 |
| Objective response rate Disease control rate |
12 (27.9) 24 (55.8) |
20 (60.6) 28 (84.8) |
0.004 0.007 |
10 (34.5) 17 (58.6) |
17 (58.6) 24 (82.8) |
0.065 0.043 |
Data are numbers of patients, with percentages in parentheses. PSM, propensity score matching; T+S, transarterial chemoembolization+sorafenib; T+S+ICIs, transarterial chemoembolization+sorafenib+immune checkpoint inhibitors.